Lamivudine for chronic delta hepatitis.

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic delta hepatitis, caused by hepatitis delta virus (HDV) on a hepatitis B virus (HBV) background, is a severe liver disease with limited treatment options.
• Current therapies for chronic delta hepatitis are unsatisfactory, necessitating the exploration of new treatment strategies.

Purpose of the Study:

• To evaluate the efficacy of lamivudine, an oral nucleoside analogue, in treating chronic delta hepatitis.
• To assess the impact of lamivudine on viral load (HBV DNA and HDV RNA), liver enzyme levels, and liver histology in patients with chronic delta hepatitis.

Main Methods:

• A study involving 5 male patients with chronic delta hepatitis (HBsAg, anti-HDV, HDV RNA positive, elevated ALT, and significant liver fibrosis/cirrhosis).
• Patients received 100 mg of lamivudine orally daily for 12 months.
• Serial monitoring of HBsAg, HBV DNA, HDV RNA, and ALT levels, along with liver biopsies before and after treatment.

Main Results:

• Lamivudine rapidly reduced serum HBV DNA levels in all patients, with undetectable levels by PCR in 4 out of 5.
• Despite HBV DNA reduction, all patients remained positive for HBsAg and HDV RNA.
• No improvement was observed in serum ALT levels or liver histology after 12 months of lamivudine treatment.
• Upon cessation of lamivudine, HBV DNA levels reverted to baseline without changes in disease activity.

Conclusions:

• Lamivudine is a potent inhibitor of HBV DNA replication in chronic delta hepatitis patients.
• Lamivudine therapy does not significantly improve liver disease activity or reduce HDV RNA levels in this patient population.
• Further research is needed to identify effective therapies for chronic delta hepatitis.